FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Immunity, inflammation and disease2017; 6(1); 81-96; doi: 10.1002/iid3.198

A comparison of nanoparticullate CpG immunotherapy with and without allergens in spontaneously equine asthma-affected horses, an animal model.

Abstract: New therapeutic strategies to modulate the immune response of human and equine allergic asthma are still under extensive investigation. Immunomodulating agents stimulating T-regulatory cells offer new treatment options beyond conventional symptomatic treatment or specific immunotherapy for human and equine allergic airway diseases, with the goal of a homoeostatic T-helper cell balance. The aim of this study was to evaluate the effects of a nebulized gelatin nanoparticle-CpG formulation (CpG-GNP) with and without specific allergens for the treatment of spontaneous allergic equine asthma as a model for human asthma. Twenty equine asthma-affected horses were treated either with CpG-GNP alone or CpG-GNP with allergens. Two specific allergens were selected for each horse based on history and an in-vitro test. Each horse received seven administrations of the respective nebulized composition and was examined before treatment, immediately after and 6 weeks after the treatment course. Clinical parameters such as breathing rate, indirect interpleural measurement, arterial blood gases, amount of tracheal mucus and percentage of neutrophils and cytokines in tracheal washes and serum samples were evaluated. Treatment with CpG-GNP alone as well as in combinations with relevant allergens resulted in clinical improvement of nasal discharge, breathing rate, amount of secretion and viscosity, neutrophil percentage and partial oxygen pressure directly after and 6 weeks after treatment. There were no significant differences between the two treatments in clinical parameters or local cytokine profiles in the tracheal wash fluid (IL-10, IFN-g, and IL-17). IL-4 concentrations decreased significantly in both groups. Nonspecific CpG-GNP-based immunotherapy shows potential as a treatment for equine and possibly also human allergic asthma.
© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2017-11-01 PubMed ID: 29094511PubMed Central: PMC5818452DOI: 10.1002/iid3.198Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Veterinary
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study explores the effectiveness of nanoparticle-CpG immunotherapy, with and without allergens, in treating equine asthma, a condition seen as a model for human asthma. The results indicated that CpG nanoparticle-based immunotherapy can potentially improve asthma symptoms and may be applied in human treatment strategies.

Research Objectives and Approach:

  • The research aimed to assess the impact of nebulized gelatin nanoparticle-CpG formulation, applied with or without allergies, on equine asthma.
  • Twenty horses with asthma were treated either with the nanoparticle formulation alone or with the addition of allergens, based on their history and in-vitro tests.
  • Each horse was subjected to seven administrations of the treatment and was examined prior to treatment, instantaneously afterwards, and six weeks post-treatment.

Methodology and Measurements:

  • Investigators tracked various clinical indicators such as breathing rate, blood gas levels, the volume of tracheal mucus, the count of neutrophils and cytokines in tracheal washes, and serum samples.

Findings:

  • Both the treatment formats led to improvements in symptoms like nasal discharge, rate of respiration, level of secretion and viscosity, the percentage of neutrophils, and partial oxygen pressure, both immediately and six weeks after treatment.
  • No significant differences were noted between the two treatment formats in terms of clinical outcomes or local cytokine profiles (IL-10, IFN-g, and IL-17) in the tracheal wash fluid.
  • The concentration of IL-4 decreased significantly in both treatment groups.

Implications:

  • The study results suggest that nanoparticle-CpG immunotherapy can potentially be used in the treatment of asthma in horses and possibly also in humans.
  • The treatment appears to be effective both with and without the addition of specific allergens, offering flexibility in treatment plans.

Conclusions:

  • The research demonstrated that non-specific CpG-GNP-based immunotherapy has promise as a potential strategy for managing allergic asthma in both horses and potentially humans.

Cite This Article

APA
Klier J, Geis S, Steuer J, Geh K, Reese S, Fuchs S, Mueller RS, Winter G, Gehlen H. (2017). A comparison of nanoparticullate CpG immunotherapy with and without allergens in spontaneously equine asthma-affected horses, an animal model. Immun Inflamm Dis, 6(1), 81-96. https://doi.org/10.1002/iid3.198

Publication

Immunity, inflammation and disease
ISSN: 2050-4527
NlmUniqueID: 101635460
Country: England
Language: English
Volume: 6
Issue: 1
Pages: 81-96

Researcher Affiliations

Klier, John
  • Centre for Clinical Veterinary Medicine, Equine Clinic, Ludwig-Maximilians-University, Munich, Germany.
Geis, Sabine
  • Centre for Clinical Veterinary Medicine, Equine Clinic, Ludwig-Maximilians-University, Munich, Germany.
  • Department of Veterinary Medicine, Equine Clinic, Surgery and Radiology, Free University of Berlin, Berlin, Germany.
Steuer, Jeanette
  • Centre for Clinical Veterinary Medicine, Equine Clinic, Ludwig-Maximilians-University, Munich, Germany.
  • Department of Veterinary Medicine, Equine Clinic, Surgery and Radiology, Free University of Berlin, Berlin, Germany.
Geh, Katharina
  • Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University, Munich, Germany.
Reese, Sven
  • Department of Veterinary Science, Institute of Anatomy, Histology and Embryology, Ludwig-Maximilians-University, Munich, Germany.
Fuchs, Sebastian
  • Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University, Munich, Germany.
Mueller, Ralf S
  • Centre for Clinical Veterinary Medicine, Small Animal Medicine Clinic, Ludwig-Maximilians-University, Munich, Germany.
Winter, Gerhard
  • Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University, Munich, Germany.
Gehlen, Heidrun
  • Department of Veterinary Medicine, Equine Clinic, Surgery and Radiology, Free University of Berlin, Berlin, Germany.

MeSH Terms

  • Allergens / pharmacology
  • Animals
  • Asthma / immunology
  • Asthma / therapy
  • Asthma / veterinary
  • Cytokines / immunology
  • Desensitization, Immunologic
  • Disease Models, Animal
  • Female
  • Horse Diseases / immunology
  • Horse Diseases / therapy
  • Horses
  • Male
  • Nanoparticles / therapeutic use
  • Oligodeoxyribonucleotides / pharmacology
  • Random Allocation

References

This article includes 63 references
  1. Braman SS. The global burden of asthma.. Chest 2006 Jul;130(1 Suppl):4S-12S.
    pubmed: 16840363doi: 10.1378/chest.130.1_suppl.4sgoogle scholar: lookup
  2. nnRobinson, N. E.nn2001. nRecurrent airway obstruction (Heaves)ninnLekeux P., ed. nEquine respiratory diseases. nPublisher: International Veterinary Information Service; (www.ivis.org), nIthaca, New York.n
  3. Leclere M, Lavoie-Lamoureux A, Lavoie JP. Heaves, an asthma-like disease of horses.. Respirology 2011 Oct;16(7):1027-46.
    pubmed: 21824219doi: 10.1111/j.1440-1843.2011.02033.xgoogle scholar: lookup
  4. Bullone M, Lavoie JP. Asthma "of horses and men"--how can equine heaves help us better understand human asthma immunopathology and its functional consequences?. Mol Immunol 2015 Jul;66(1):97-105.
    pubmed: 25547716doi: 10.1016/j.molimm.2014.12.005google scholar: lookup
  5. Gerber V, Ramseyer A, Laumen E, Nussbaumer P, Klukowska‐Rötzler J, Swinburne JE, Marti E, Leeb T, Dolf G. Genetics of equine RAO. Pp. 34–6. in Tessier C., and Gerber V., eds. 4th world equine airways symposium (WEAS). Pabst Science Publishers, Bern..
  6. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, Pfister T, Maurer P, Bachmann MF, Graf N, Kündig TM. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.. Clin Exp Allergy 2009 Apr;39(4):562-70.
    pubmed: 19226280doi: 10.1111/j.1365-2222.2008.03191.xgoogle scholar: lookup
  7. Klier J, Fuchs S, May A, Schillinger U, Plank C, Winter G, Coester C, Gehlen H. A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses.. Pharm Res 2012 Jun;29(6):1650-7.
    pubmed: 22302522doi: 10.1007/s11095-012-0686-8google scholar: lookup
  8. Klier J, Lehmann B, Fuchs S, Reese S, Hirschmann A, Coester C, Winter G, Gehlen H. Nanoparticulate CpG immunotherapy in RAO-affected horses: phase I and IIa study.. J Vet Intern Med 2015 Jan;29(1):286-93.
    pmc: PMC4858074pubmed: 25619520doi: 10.1111/jvim.12524google scholar: lookup
  9. Schneberger D, Caldwell S, Suri SS, Singh B. Expression of toll-like receptor 9 in horse lungs.. Anat Rec (Hoboken) 2009 Jul;292(7):1068-77.
    pubmed: 19548205doi: 10.1002/ar.20927google scholar: lookup
  10. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells.. Immunology 2006 Apr;117(4):433-42.
    pmc: PMC1782242pubmed: 16556256doi: 10.1111/j.1365-2567.2006.02321.xgoogle scholar: lookup
  11. Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, Coester C. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.. Pharm Res 2008 Mar;25(3):551-62.
    pubmed: 17912489doi: 10.1007/s11095-007-9410-5google scholar: lookup
  12. Klier J, May A, Fuchs S, Schillinger U, Plank C, Winter G, Gehlen H, Coester C. Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles.. Vet Immunol Immunopathol 2011 Nov 15;144(1-2):79-87.
    pubmed: 21831455doi: 10.1016/j.vetimm.2011.07.009google scholar: lookup
  13. Hampel S. Prüfung und Modulation der Typ‐I‐Reaktionsbereitschaft von Pferden im funktionellen in vitro Test (FIT) sowie im Intrakutantest (IKT). Thesis, Stiftung Tierärztliche Hochschule Hannover.
  14. Gerber V, King M, Schneider DA, Robinson NE. Tracheobronchial mucus viscoelasticity during environmental challenge in horses with recurrent airway obstruction.. Equine Vet J 2000 Sep;32(5):411-7.
    pubmed: 11037263doi: 10.2746/042516400777591183google scholar: lookup
  15. Grabner A. Arterielle blutgasanalyse. Pp. 429–30. in Kraft W., and Dürr UM, eds. Klinische labordiagnostik in der tiermedizin. Schattauer, Stuttgart..
  16. Gerber V, Straub R, Marti E, Hauptman J, Herholz C, King M, Imhof A, Tahon L, Robinson NE. Endoscopic scoring of mucus quantity and quality: observer and horse variance and relationship to inflammation, mucus viscoelasticity and volume.. Equine Vet J 2004 Nov;36(7):576-82.
    pubmed: 15581321doi: 10.2746/0425164044864525google scholar: lookup
  17. Deegen, E. , and Klein H. J.. 1987. Interpleuraldruckmessungen und Bronchospasmolysetests mit einem portalen Osophagusdruckmessgerat. Pferdeheilkunde 21:213–221.
  18. Klier J. Neuer Therapieansatz zur Behandlung der COB des Pferdes durch Immunstimulation von BAL‐Zellen mit verschiedenen CpG‐Klassen. Munich: School of Veterinary Medicine, Ludwig‐Maximilians University. Thesis.
  19. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists.. Biol Rev Camb Philos Soc 2007 Nov;82(4):591-605.
    pubmed: 17944619doi: 10.1111/j.1469-185x.2007.00027.xgoogle scholar: lookup
  20. Fuchs S, Klier J, May A, Winter G, Coester C, Gehlen H. Towards an inhalative in vivo application of immunomodulating gelatin nanoparticles in horse-related preformulation studies.. J Microencapsul 2012;29(7):615-25.
    pubmed: 22432849doi: 10.3109/02652048.2012.668962google scholar: lookup
  21. Derksen FJ, Robinson NE, Scott JS, Stick JA. Aerosolized Micropolyspora faeni antigen as a cause of pulmonary dysfunction in ponies with recurrent airway obstruction (heaves).. Am J Vet Res 1988 Jun;49(6):933-8.
    pubmed: 3400931
  22. McGorum BC, Dixon PM, Halliwell RE. Responses of horses affected with chronic obstructive pulmonary disease to inhalation challenges with mould antigens.. Equine Vet J 1993 Jul;25(4):261-7.
    pubmed: 8354208doi: 10.1111/j.2042-3306.1993.tb02960.xgoogle scholar: lookup
  23. McGorum BC, Dixon PM, Halliwell RE. Phenotypic analysis of peripheral blood and bronchoalveolar lavage fluid lymphocytes in control and chronic obstructive pulmonary disease affected horses, before and after 'natural (hay and straw) challenges'.. Vet Immunol Immunopathol 1993 Apr;36(3):207-22.
    pubmed: 7685131doi: 10.1016/0165-2427(93)90020-5google scholar: lookup
  24. McGorum BC, Dixon PM. Evaluation of local endobronchial antigen challenges in the investigation of equine chronic obstructive pulmonary disease.. Equine Vet J 1993 Jul;25(4):269-72.
    pubmed: 8354209doi: 10.1111/j.2042-3306.1993.tb02961.xgoogle scholar: lookup
  25. Schmallenbach KH, Rahman I, Sasse HH, Dixon PM, Halliwell RE, McGorum BC, Crameri R, Miller HR. Studies on pulmonary and systemic Aspergillus fumigatus-specific IgE and IgG antibodies in horses affected with chronic obstructive pulmonary disease (COPD).. Vet Immunol Immunopathol 1998 Dec 11;66(3-4):245-56.
    pubmed: 9880102doi: 10.1016/s0165-2427(98)00202-5google scholar: lookup
  26. Bruennlein G. Funktioneller in‐vitro‐Test (FIT) für Typ I‐Allergien beim Pferd. Tierärztl. Hochschule Hannover. Thesis.
  27. Künzle F, Gerber V, Van Der Haegen A, Wampfler B, Straub R, Marti E. IgE-bearing cells in bronchoalveolar lavage fluid and allergen-specific IgE levels in sera from RAO-affected horses.. J Vet Med A Physiol Pathol Clin Med 2007 Feb;54(1):40-7.
    pubmed: 17359454doi: 10.1111/j.1439-0442.2007.00870.xgoogle scholar: lookup
  28. Beeler-Marfisi J, Clark ME, Wen X, Sears W, Huber L, Ackerley C, Viel L, Bienzle D. Experimental induction of recurrent airway obstruction with inhaled fungal spores, lipopolysaccharide, and silica microspheres in horses.. Am J Vet Res 2010 Jun;71(6):682-9.
    pubmed: 20513185doi: 10.2460/ajvr.71.6.682google scholar: lookup
  29. Pirie RS, Collie DD, Dixon PM, McGorum BC. Inhaled endotoxin and organic dust particulates have synergistic proinflammatory effects in equine heaves (organic dust-induced asthma).. Clin Exp Allergy 2003 May;33(5):676-83.
    pubmed: 12752598doi: 10.1046/j.1365-2222.2003.01640.xgoogle scholar: lookup
  30. Simonen-Jokinen T, Pirie RS, McGorum B, Maisi P. Dose responses to inhalation of endotoxin, hay dust suspension and Aspergillus fumigatus extract in horses as measured by levels and activation of matrix metalloproteinase-9.. Equine Vet J 2005 Mar;37(2):155-60.
    pubmed: 15779629doi: 10.2746/0425164054223796google scholar: lookup
  31. Marti E. Role of IgE and perspectives on clinical allergy testing. Pp. 109–11. in Tessier C., and Gerber V., eds. 4th world equine airways symposium (WEAS). Pabst Science Publishers, Bern..
  32. Gonsior E, Henzgen M, Jörres RA, Kroidl RF, Merget R, Riffelmann FW, Wallenstein G. [Guidelines for conducting provocation tests with allergens. German Society of Allergology and Clinical Immunology and German Society for Immunology].. Pneumologie 2002 Mar;56(3):187-98.
    pubmed: 11877737doi: 10.1055/s-2002-20553google scholar: lookup
  33. Moran G, Folch H. Recurrent airway obstruction in horses − an allergic inflammation: a review. Vet Med‐Czech 56:1–13.
  34. Marti E, Gerber H, Essich G, Oulehla J, Lazary S. The genetic basis of equine allergic diseases. 1. Chronic hypersensitivity bronchitis.. Equine Vet J 1991 Nov;23(6):457-60.
    pubmed: 1778165doi: 10.1111/j.2042-3306.1991.tb03761.xgoogle scholar: lookup
  35. Lavoie JP, Maghni K, Desnoyers M, Taha R, Martin JG, Hamid QA. Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile.. Am J Respir Crit Care Med 2001 Oct 15;164(8 Pt 1):1410-3.
    pubmed: 11704587doi: 10.1164/ajrccm.164.8.2012091google scholar: lookup
  36. Giguère S, Viel L, Lee E, MacKay RJ, Hernandez J, Franchini M. Cytokine induction in pulmonary airways of horses with heaves and effect of therapy with inhaled fluticasone propionate.. Vet Immunol Immunopathol 2002 Mar;85(3-4):147-58.
    pubmed: 11943316doi: 10.1016/s0165-2427(01)00420-2google scholar: lookup
  37. Ainsworth DM, Grünig G, Matychak MB, Young J, Wagner B, Erb HN, Antczak DF. Recurrent airway obstruction (RAO) in horses is characterized by IFN-gamma and IL-8 production in bronchoalveolar lavage cells.. Vet Immunol Immunopathol 2003 Nov 15;96(1-2):83-91.
    pubmed: 14522137doi: 10.1016/s0165-2427(03)00142-9google scholar: lookup
  38. Cordeau ME, Joubert P, Dewachi O, Hamid Q, Lavoie JP. IL-4, IL-5 and IFN-gamma mRNA expression in pulmonary lymphocytes in equine heaves.. Vet Immunol Immunopathol 2004 Jan;97(1-2):87-96.
    pubmed: 14700540doi: 10.1016/j.vetimm.2003.08.013google scholar: lookup
  39. Horohov DW, Beadle RE, Mouch S, Pourciau SS. Temporal regulation of cytokine mRNA expression in equine recurrent airway obstruction.. Vet Immunol Immunopathol 2005 Oct 18;108(1-2):237-45.
    pubmed: 16098607doi: 10.1016/j.vetimm.2005.07.013google scholar: lookup
  40. Bohle B. CpG motifs as possible adjuvants for the treatment of allergic diseases.. Int Arch Allergy Immunol 2002 Nov;129(3):198-203.
    pubmed: 12444316doi: 10.1159/000066771google scholar: lookup
  41. Jahn-Schmid B, Wiedermann U, Bohle B, Repa A, Kraft D, Ebner C. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen.. J Allergy Clin Immunol 1999 Nov;104(5):1015-23.
    pubmed: 10550747doi: 10.1016/s0091-6749(99)70083-7google scholar: lookup
  42. Kohama Y, Akizuki O, Hagihara K, Yamada E, Yamamoto H. Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice.. J Allergy Clin Immunol 1999 Dec;104(6):1231-8.
    pubmed: 10589006doi: 10.1016/s0091-6749(99)70018-7google scholar: lookup
  43. Reinero CR, Cohn LA, Delgado C, Spinka CM, Schooley EK, DeClue AE. Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma.. Vet Immunol Immunopathol 2008 Feb 15;121(3-4):241-50.
    pubmed: 17981343doi: 10.1016/j.vetimm.2007.09.013google scholar: lookup
  44. Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation.. Trends Immunol 2003 Jul;24(7):376-9.
    pubmed: 12860528doi: 10.1016/s1471-4906(03)00142-xgoogle scholar: lookup
  45. Meurer DG, Wolf S. Allgemeine Pathologie: Kompendium für die Veterinärmedizin. Schattauer Verlag, Stuttgart: 161–172.
  46. Halliwell RE, McGorum BC, Irving P, Dixon PM. Local and systemic antibody production in horses affected with chronic obstructive pulmonary disease.. Vet Immunol Immunopathol 1993 Oct;38(3-4):201-15.
    pubmed: 8291200doi: 10.1016/0165-2427(93)90081-egoogle scholar: lookup
  47. Lunn P, Horohov D. The equine immune system. Pp. 2–56. in Reed SM, Bayly WM, and Sellon DC, eds. Equine internal medicine. Saunders Elsevier, St. Louis, Missouri..
  48. Jonsdottir S, Hamza E, Janda J, Rhyner C, Meinke A, Marti E, Svansson V, Torsteinsdottir S. Developing a preventive immunization approach against insect bite hypersensitivity using recombinant allergens: A pilot study.. Vet Immunol Immunopathol 2015 Jul 15;166(1-2):8-21.
    pubmed: 26004943doi: 10.1016/j.vetimm.2015.05.002google scholar: lookup
  49. Mueller RS, Veir J, Fieseler KV, Dow S. The use of immunostimulatory bacterial DNA sequences in allergen‐specific immunotherapy of canine atopic dermatitis. Vet Derm 16:61–68.
  50. Shida M, Kadoya M, Park SJ, Nishifuji K, Momoi Y, Iwasaki T. Allergen-specific immunotherapy induces Th1 shift in dogs with atopic dermatitis.. Vet Immunol Immunopathol 2004 Nov;102(1-2):19-31.
    pubmed: 15451612doi: 10.1016/j.vetimm.2004.06.003google scholar: lookup
  51. Deaton CM, Deaton L, Jose-Cunilleras E, Vincent TL, Baird AW, Dacre K, Marlin DJ. Early onset airway obstruction in response to organic dust in the horse.. J Appl Physiol (1985) 2007 Mar;102(3):1071-7.
    pubmed: 17158251doi: 10.1152/japplphysiol.00264.2006google scholar: lookup
  52. Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF. Is The Allergen Really Needed in Allergy Immunotherapy?. Curr Treat Options Allergy 2015;2(1):72-82.
    pmc: PMC4335088pubmed: 25722959doi: 10.1007/s40521-014-0038-5google scholar: lookup
  53. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, Creticos PJ, Dayer JM, Durham SR, Demoly P, Goldstein RJ, Ishikawa T, Ito K, Kraft D, Lambert PH, Løwenstein H, Müller U, Norman PS, Reisman RE, Valenta R, Valovirta E, Yssel H. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology.. Ann Allergy Asthma Immunol 1998 Nov;81(5):401-5.
    pubmed: 9860031doi: 10.1016/s1081-1206(10)63136-5google scholar: lookup
  54. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells.. J Immunol 2004 Oct 1;173(7):4433-42.
    pubmed: 15383574doi: 10.4049/jimmunol.173.7.4433google scholar: lookup
  55. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.. Eur J Immunol 1997 May;27(5):1131-9.
    pubmed: 9174602doi: 10.1002/eji.1830270513google scholar: lookup
  56. Keppel KE, Campbell KL, Zuckermann FA, Greeley EA, Schaeffer DJ, Husmann RJ. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy.. Vet Immunol Immunopathol 2008 Jun 15;123(3-4):337-44.
    pubmed: 18423890doi: 10.1016/j.vetimm.2008.02.008google scholar: lookup
  57. Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma.. J Allergy Clin Immunol 1996 Jun;97(6):1288-96.
    pubmed: 8648025doi: 10.1016/s0091-6749(96)70197-5google scholar: lookup
  58. Teixeira LK, Fonseca BP, Barboza BA, Viola JP. The role of interferon-gamma on immune and allergic responses.. Mem Inst Oswaldo Cruz 2005 Mar;100 Suppl 1:137-44.
    pubmed: 15962113doi: 10.1590/s0074-02762005000900024google scholar: lookup
  59. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family.. J Allergy Clin Immunol 2004 Dec;114(6):1265-73; quiz 1274.
    pubmed: 15577820doi: 10.1016/j.jaci.2004.10.019google scholar: lookup
  60. Ainsworth DM, Wagner B, Franchini M, Grünig G, Erb HN, Tan JY. Time-dependent alterations in gene expression of interleukin-8 in the bronchial epithelium of horses with recurrent airway obstruction.. Am J Vet Res 2006 Apr;67(4):669-77.
    pubmed: 16579761doi: 10.2460/ajvr.67.4.669google scholar: lookup
  61. Debrue M, Hamilton E, Joubert P, Lajoie-Kadoch S, Lavoie JP. Chronic exacerbation of equine heaves is associated with an increased expression of interleukin-17 mRNA in bronchoalveolar lavage cells.. Vet Immunol Immunopathol 2005 May 1;105(1-2):25-31.
    pubmed: 15797472doi: 10.1016/j.vetimm.2004.12.013google scholar: lookup
  62. Bowles KS, Beadle RE, Mouch S, Pourciau SS, Littlefield-Chabaud MA, Le Blanc C, Mistric L, Fermaglich D, Horohov DW. A novel model for equine recurrent airway obstruction.. Vet Immunol Immunopathol 2002 Sep 10;87(3-4):385-9.
    pubmed: 12072262doi: 10.1016/s0165-2427(02)00081-8google scholar: lookup
  63. Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine.. Vet Dermatol 2009 Apr;20(2):84-98.
    pubmed: 19320877doi: 10.1111/j.1365-3164.2008.00727.xgoogle scholar: lookup

Citations

This article has been cited 11 times.
  1. Klier J, Fuchs S, Winter G, Gehlen H. Inhalative Nanoparticulate CpG Immunotherapy in Severe Equine Asthma: An Innovative Therapeutic Concept and Potential Animal Model for Human Asthma Treatment. Animals (Basel) 2022 Aug 16;12(16).
    doi: 10.3390/ani12162087pubmed: 36009677google scholar: lookup
  2. Simões J, Batista M, Tilley P. The Immune Mechanisms of Severe Equine Asthma-Current Understanding and What Is Missing. Animals (Basel) 2022 Mar 16;12(6).
    doi: 10.3390/ani12060744pubmed: 35327141google scholar: lookup
  3. Reddy PRK, Yasaswini D, Reddy PPR, Zeineldin M, Adegbeye MJ, Hyder I. Applications, challenges, and strategies in the use of nanoparticles as feed additives in equine nutrition. Vet World 2020 Aug;13(8):1685-1696.
    doi: 10.14202/vetworld.2020.1685-1696pubmed: 33061246google scholar: lookup
  4. Barton AK, Shety T, Klier J, Geis S, Einspanier R, Gehlen H. Metalloproteinases and their Inhibitors under the Course of Immunostimulation by CPG-ODN and Specific Antigen Inhalation in Equine Asthma. Mediators Inflamm 2019;2019:7845623.
    doi: 10.1155/2019/7845623pubmed: 31316303google scholar: lookup
  5. Klier J, Bartl C, Geuder S, Geh KJ, Reese S, Goehring LS, Winter G, Gehlen H. Immunomodulatory asthma therapy in the equine animal model: A dose-response study and evaluation of a long-term effect. Immun Inflamm Dis 2019 Sep;7(3):130-149.
    doi: 10.1002/iid3.252pubmed: 31141308google scholar: lookup
  6. Wu Y, Yue J, Wu J, Zhou W, Li D, Ding K, Barnie PA, Xu X, Xu H, Shi W. Obesity May Provide Pro-ILC3 Development Inflammatory Environment in Asthmatic Children. J Immunol Res 2018;2018:1628620.
    doi: 10.1155/2018/1628620pubmed: 30622974google scholar: lookup
  7. Bond S, Léguillette R, Richard EA, Couetil L, Lavoie JP, Martin JG, Pirie RS. Equine asthma: Integrative biologic relevance of a recently proposed nomenclature. J Vet Intern Med 2018 Nov;32(6):2088-2098.
    doi: 10.1111/jvim.15302pubmed: 30294851google scholar: lookup
  8. Kazemi M. Revolutionizing Veterinary Medicine: The Role of Nanoparticles in Advancing Animal Health, Nutrition and Disease Management. Vet Med Sci 2025 Sep;11(5):e70528.
    doi: 10.1002/vms3.70528pubmed: 40747873google scholar: lookup
  9. Jentsch MC, Lübke S, Schrödl W, Volke D, Krizsan A, Hoffmann R, Kaiser-Thom S, Gerber V, Marti E, Wagner B, Schnabel CL. Immunoproteomics enable broad identification of new Aspergillus fumigatus antigens in severe equine asthma. Front Immunol 2024;15:1347164.
    doi: 10.3389/fimmu.2024.1347164pubmed: 38487534google scholar: lookup
  10. Simões J, Tilley P. Decision Making in Severe Equine Asthma-Diagnosis and Monitoring. Animals (Basel) 2023 Dec 16;13(24).
    doi: 10.3390/ani13243872pubmed: 38136909google scholar: lookup
  11. Herrmann I, Sanchez AJ. Efficacy and Safety of Subcutaneous Allergen-Specific Immuno-Therapy in Horses with Allergic Cutaneous and Respiratory Diseases-A Systematic Review. Vet Sci 2023 Oct 10;10(10).
    doi: 10.3390/vetsci10100613pubmed: 37888565google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.